Alcobra’s ADHD drug meets goals in late-stage study

(Reuters) – Alcobra Ltd said its drug to treat attention deficit disorder met the main goals of a late-stage trial, reducing the symptoms of the condition better than a sugar pill. The study results were derived after the company excluded data from four patients who showed an extreme response to the placebo, Alcobra said in a statement. The company said the study scored the drug, Metadoxine, on the same scale used in studies that evaluated other attention deficit hyperactivity disorder, or ADHD, drugs. (Reporting by Vidya L Nathan in Bangalore; Editing by Savio D’Souza)
Medications/Drugs News Headlines – Yahoo! News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us